Better Dividend Growth Stock to Buy: CVS Health or UnitedHealth Group?

UnitedHealth Group has a clear dividend-growth edge, with 16 consecutive years of annual dividend increases versus no raise at CVS for over two years. CVS offers the higher forward yield at about 2.9% versus 2.3% for UNH, but UNH's 10-year dividend growth rate of 16.6% far exceeds CVS's 6.63%. The article is constructive on both stocks operationally, but it favors UNH for income growth while noting CVS may have more upside from valuation rerating at 12.5x forward earnings.

Analysis

The market is implicitly treating this as a simple yield-versus-growth comparison, but the more important signal is capital allocation credibility. UNH’s recurring dividend raises imply management confidence in normalized cash generation and a lower probability of balance-sheet stress, which matters in managed care because reimbursement shocks can compound quickly through reserves, M&A capacity, and pricing leverage. CVS, by contrast, is still in the market’s “prove it” bucket: the yield screens cheaper, but the lack of payout growth suggests equity holders are being compensated mainly for optionality on a turnaround, not for durable compounding.

Second-order, the valuation gap can persist longer than fundamentals if investors keep using UNH as the sector quality proxy. That makes UNH less attractive as a near-term rerating story even if it remains the cleaner dividend compounder. CVS has more torque to improving sentiment because a modest multiple expansion from depressed levels can dominate the carry; however, that upside is fragile and depends on continued execution across several moving parts, not just a single quarter of better reimbursement noise.

The contrarian read is that the article underweights payout durability risk at CVS and overweights near-term yield appeal. A higher forward yield is only useful if the business can sustain and grow the base; if earnings volatility resurfaces, that yield can become a value trap quickly. For UNH, the main risk is that investors pay up for perceived safety and dividend consistency just as growth normalizes, capping total return despite strong income characteristics.

Key Decisions for Investors

• Overweight UNH vs. CVS on a 6-12 month horizon for dividend-quality exposure; prefer a lower current yield in exchange for higher probability of 8-12% annual dividend growth and lower cut risk.
• Pair trade: long UNH / short CVS into strength over the next 1-3 months; thesis is that the market will continue to reward consistency while CVS remains hostage to execution and multiple skepticism.
• For higher-risk upside, buy CVS only on pullbacks below current forward multiple; target a 15-20% rerating if guidance stabilizes, but cut the position if reimbursement or margin headlines re-accelerate downside.
• If seeking income with less equity beta, sell out-of-the-money covered calls against UNH rather than chasing CVS yield; this preserves quality while harvesting premium from a richly valued defensive name.
• Use a spread trade around earnings: long UNH calls / short CVS calls into the next print if you expect continued dispersion in investor confidence and a 2-4 week reaction window.